Actively Recruiting
Evaluating Neoadjuvant Nimotuzumab, Toripalimab, and Chemotherapy for Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma A Prospective Single-Arm Study
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-10-30
86
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of combining targeted therapy, immunotherapy, and chemotherapy as a neoadjuvant treatment for patients with locally advanced, resectable head and neck squamous cell carcinoma HNSCC. This phase II, single-arm prospective study focuses on patients aged 18 to 75 with stage III-IVB disease. The goal is to study the major pathological response rate and other important outcomes in this patient group. Participants will receive up to three 3-week cycles of neoadjuvant therapy including nimotuzumab given weekly on days 1, 8, and 15 toripalimab on day 1 and chemotherapy drugs nab-paclitaxel and cisplatin on day 1 of each cycle. About one month after the last neoadjuvant treatment, patients will undergo radical surgery. Postoperative treatments will be chosen based on individual high-risk pathological factors. The study includes regular follow-up to monitor efficacy and safety. During the study, patients will have assessments including pathological evaluations at surgery, imaging according to RECIST 1.1, and safety monitoring using standard criteria. Researchers will also collect data on survival rates, quality of life, and prognostic biomarkers before and after treatment. Participation is expected to last at least two years after enrollment of the last patient, allowing long-term outcome tracking.
CONDITIONS
Brief Title
Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Study
Research Team
S
Sheng Yang
S
Sidan li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here